


## Background

- Haemophilia is a recessive X-linked disorder characterised by a reduced ability to generate thrombin leading to prolonged bleeding events. Haemophilia A (HA) and haemophilia B (HB) are characterised by deficiency of clotting factor VIII (FVIII) or clotting factor IX (FIX), respectively<sup>1</sup>.
  - The prevalence of haemophilia varies across Latin and South America, with prevalence estimates in select South American countries ranging from 6.2 (Argentina, Brazil) to 9.4 (Chile) per 100,000 people<sup>2</sup>.
  - Though the comprehensive burden of haemophilia has been studied in Europe and North America, the impact of severe haemophilia in Latin and South America has not been well characterised. Robust data on the real-world burden and cost of haemophilia is needed to understand the impact and unmet needs of existing treatment patterns, and the potential improvements of emerging therapies.
- ### Aims and Objectives


  - To quantify the socioeconomic burden of severe haemophilia across Latin America.
  - To estimate the health-related quality of life of people with severe haemophilia across Latin America.
- ### Methods

  - The study was designed as a retrospective, cross-sectional, bottom-up prevalence-based burden of illness study.
  - Haematologists were recruited using a panel-based approach, with patients recruited prospectively, with the index date defined as the date of clinical consultation, either in-person or via the phone.
  - Case report forms (completed by haematologist) captured clinical, demographic, and direct medical cost data associated with haemophilia in each country.

- Linked patient-completed (voluntary) forms capturing direct non-medical and indirect costs, as well as patient reported outcomes including the EQ-5D-5L and the work productivity and Activity Impairment (WPAI).
- The study design for the CHESS LATAM study is presented in Figure 1.



- Data was collected between September 2020 and May 2021, with resource use collected over the 12 months prior to the index date. Health-related quality of life was captured at the index date, as shown in Figure 2.



- Socioeconomic burden was calculated by capturing per-patient healthcare resource use and multiplying by country-specific unit costs. Some direct non-medical and indirect costs were captured directly from patients via the PPIE.
- Health state utility values were captured by applying the Uruguayan EQ-5D-5L preference set<sup>3</sup> to reported EQ-5D-5L data. The Uruguayan value set<sup>3</sup> was used as no country-specific value set was available for the four countries captured in the study at time of analysis.

## Results

- The number of completed eCRFs and PPIEs captured during the CHESS LATAM study are reported in Table 1.

**Table 1. CHESS LATAM population**

Characteristic, n (%) unless noted otherwise	All Patients (N=830)	Argentina (n=259)	Brazil (n=262)	Chile (n=107)
Completed eCRFs (physicians)	830 (100)	259/830 (31)	262/830 (32)	107/830 (13)
Completed PPIEs (patients)	153/830 (18)	31/259 (12)	18/262 (7)	104/107 (97)
Haemophilia A	676 (81)	215 (83)	214 (82)	69 (64)
Haemophilia B	154 (19)	44 (17)	48 (18)	38 (36)